Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3040% below fair value
$1.73+0.03 (+1.76%)
Close on Nov 13, 2026Market cap $106.60MP/E –Yield –
Voyager Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Voyager Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $106.97M, down 20.4% year over year. For fiscal 2025 it was $134.67M, up 5.7% from the year before. Over ten years it grew 17.1% a year on average. The highest annual figure on record is $134.67M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.67M | +5.7% |
| FY2024 | Dec 31, 2024 | $127.37M | +38.2% |
| FY2023 | Dec 31, 2023 | $92.17M | +51.7% |
| FY2022 | Dec 31, 2022 | $60.76M | -17.6% |
| FY2021 | Dec 31, 2021 | $73.79M | -32.2% |
| FY2020 | Dec 31, 2020 | $108.75M | -9.2% |
| FY2019 | Dec 31, 2019 | $119.74M | +84.5% |
| FY2018 | Dec 31, 2018 | $64.91M | +4.2% |
| FY2017 | Dec 31, 2017 | $62.26M | +47.4% |
| FY2016 | Dec 31, 2016 | $42.25M | +52.6% |
| FY2015 | Dec 31, 2015 | $27.68M | +211.1% |
| FY2014 | Dec 31, 2014 | $8.90M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $24.37M | -32.0% |
| Q2 FY2026 | Jun 30, 2026 | $22.04M | -29.6% |
| Q1 FY2026 | Mar 31, 2026 | $24.60M | -22.0% |
| Q4 FY2025 | Dec 31, 2025 | $35.95M | +1.0% |
| Q3 FY2025 | Sep 30, 2025 | $35.87M | +18.6% |
| Q2 FY2025 | Jun 30, 2025 | $31.33M | -9.1% |
| Q1 FY2025 | Mar 31, 2025 | $31.53M | +16.4% |
| Q4 FY2024 | Dec 31, 2024 | $35.58M | +38.2% |
| Q3 FY2024 | Sep 30, 2024 | $30.24M | +16.9% |
| Q2 FY2024 | Jun 30, 2024 | $34.45M | +56.7% |
| Q1 FY2024 | Mar 31, 2024 | $27.09M | +45.9% |
| Q4 FY2023 | Dec 31, 2023 | $25.76M | +77.0% |
| Q3 FY2023 | Sep 30, 2023 | $25.86M | +33.7% |
| Q2 FY2023 | Jun 30, 2023 | $21.99M | +75.5% |
| Q1 FY2023 | Mar 31, 2023 | $18.57M | +29.4% |
| Q4 FY2022 | Dec 31, 2022 | $14.55M | +3.8% |
| Q3 FY2022 | Sep 30, 2022 | $19.34M | +7.9% |
| Q2 FY2022 | Jun 30, 2022 | $12.53M | -35.8% |
| Q1 FY2022 | Mar 31, 2022 | $14.35M | -35.8% |
| Q4 FY2021 | Dec 31, 2021 | $14.02M | -36.3% |
| Q3 FY2021 | Sep 30, 2021 | $17.91M | -28.5% |
| Q2 FY2021 | Jun 30, 2021 | $19.51M | -33.7% |
| Q1 FY2021 | Mar 31, 2021 | $22.35M | -30.8% |
| Q4 FY2020 | Dec 31, 2020 | $22.00M | -39.8% |
| Q3 FY2020 | Sep 30, 2020 | $25.04M | -15.9% |
| Q2 FY2020 | Jun 30, 2020 | $29.42M | +3.0% |
| Q1 FY2020 | Mar 31, 2020 | $32.29M | +30.1% |
| Q4 FY2019 | Dec 31, 2019 | $36.55M | +116.1% |
| Q3 FY2019 | Sep 30, 2019 | $29.78M | +79.0% |
| Q2 FY2019 | Jun 30, 2019 | $28.58M | +73.1% |
| Q1 FY2019 | Mar 31, 2019 | $24.83M | +67.2% |
| Q4 FY2018 | Dec 31, 2018 | $16.91M | +26.9% |
| Q3 FY2018 | Sep 30, 2018 | $16.63M | -15.0% |
| Q2 FY2018 | Jun 30, 2018 | $16.51M | +7.9% |
| Q1 FY2018 | Mar 31, 2018 | $14.85M | +5.6% |
| Q4 FY2017 | Dec 31, 2017 | $13.33M | +4.7% |
| Q3 FY2017 | Sep 30, 2017 | $19.56M | – |
| Q2 FY2017 | Jun 30, 2017 | $15.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.07M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.72M | – |
See a number that looks wrong?